720 related articles for article (PubMed ID: 33261932)
1. Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant.
Hudgens S; Floden L; Blackowicz M; Jamieson C; Popova V; Fedgchin M; Drevets WC; Cooper K; Lane R; Singh J
J Affect Disord; 2021 Feb; 281():767-775. PubMed ID: 33261932
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant.
Floden L; Hudgens S; Jamieson C; Popova V; Drevets WC; Cooper K; Singh J
CNS Drugs; 2022 Jun; 36(6):649-658. PubMed ID: 35441931
[TBL] [Abstract][Full Text] [Related]
3. Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery-Åsberg Depression Rating Scale and the 9-item Patient Health Questionnaire.
Kern Sliwa J; Naranjo RR; Turkoz I; Petrillo MP; Cabrera P; Trivedi M
CNS Spectr; 2024 Jun; 29(3):176-186. PubMed ID: 38557430
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.
Takahashi N; Yamada A; Shiraishi A; Shimizu H; Goto R; Tominaga Y
BMC Psychiatry; 2021 Oct; 21(1):526. PubMed ID: 34696742
[TBL] [Abstract][Full Text] [Related]
6. Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression.
Turkoz I; Alphs L; Singh J; Jamieson C; Daly E; Shawi M; Sheehan JJ; Trivedi MH; Rush AJ
Acta Psychiatr Scand; 2021 Mar; 143(3):253-263. PubMed ID: 33249552
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3.
Ochs-Ross R; Daly EJ; Zhang Y; Lane R; Lim P; Morrison RL; Hough D; Manji H; Drevets WC; Sanacora G; Steffens DC; Adler C; McShane R; Gaillard R; Wilkinson ST; Singh JB
Am J Geriatr Psychiatry; 2020 Feb; 28(2):121-141. PubMed ID: 31734084
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials.
Jones RR; Freeman MP; Kornstein SG; Cooper K; Daly EJ; Canuso CM; Nicholson S
Arch Womens Ment Health; 2022 Apr; 25(2):313-326. PubMed ID: 34973081
[TBL] [Abstract][Full Text] [Related]
11. Montgomery-Åsberg Depression Rating Scale factors in treatment-resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine.
Borentain S; Gogate J; Williamson D; Carmody T; Trivedi M; Jamieson C; Cabrera P; Popova V; Wajs E; DiBernardo A; Daly EJ
Int J Methods Psychiatr Res; 2022 Dec; 31(4):e1927. PubMed ID: 35749277
[TBL] [Abstract][Full Text] [Related]
12. Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder".
Borentain S; Desai P; Fu DJ; Nancy Chen L; Lane R; Mathews M; Canuso CM
J Psychopharmacol; 2023 Aug; 37(8):836-844. PubMed ID: 36218274
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
[TBL] [Abstract][Full Text] [Related]
14. Intranasal esketamine effectively treats treatment-resistant depression in adults regardless of baseline irritability.
Jha MK; Williamson DJ; Magharehabed G; Turkoz I; Daly EJ; Trivedi MH
J Affect Disord; 2023 Jan; 321():153-160. PubMed ID: 36273682
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study.
Castro M; Wilkinson ST; Al Jurdi RK; Petrillo MP; Zaki N; Borentain S; Fu DJ; Turkoz I; Sun L; Brown B; Cabrera P
CNS Drugs; 2023 Aug; 37(8):715-723. PubMed ID: 37558912
[TBL] [Abstract][Full Text] [Related]
16. Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray.
Turkoz I; Nelson JC; Wilkinson ST; Borentain S; Macaluso M; Trivedi MH; Williamson D; Sheehan JJ; Salvadore G; Singh J; Daly E
Psychiatry Res; 2023 May; 323():115165. PubMed ID: 37019044
[TBL] [Abstract][Full Text] [Related]
17. Comparability of blinded remote and site-based assessments of response to adjunctive esketamine or placebo nasal spray in patients with treatment resistant depression.
Targum SD; Daly E; Fedgchin M; Cooper K; Singh JB
J Psychiatr Res; 2019 Apr; 111():68-73. PubMed ID: 30685564
[TBL] [Abstract][Full Text] [Related]
18. Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials.
Saad Z; Hibar D; Fedgchin M; Popova V; Furey ML; Singh JB; Kolb H; Drevets WC; Chen G
Int J Neuropsychopharmacol; 2020 Dec; 23(9):549-558. PubMed ID: 32367114
[TBL] [Abstract][Full Text] [Related]
19. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).
Fu DJ; Ionescu DF; Li X; Lane R; Lim P; Sanacora G; Hough D; Manji H; Drevets WC; Canuso CM
J Clin Psychiatry; 2020 May; 81(3):. PubMed ID: 32412700
[TBL] [Abstract][Full Text] [Related]
20. Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.
Reif A; Bitter I; Buyze J; Cebulla K; Frey R; Fu DJ; Ito T; Kambarov Y; Llorca PM; Oliveira-Maia AJ; Messer T; Mulhern-Haughey S; Rive B; von Holt C; Young AH; Godinov Y;
N Engl J Med; 2023 Oct; 389(14):1298-1309. PubMed ID: 37792613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
